The LKB1-AMPK pathway-friend or foe in cancer?
- PMID: 23410967
- DOI: 10.1016/j.ccr.2013.01.009
The LKB1-AMPK pathway-friend or foe in cancer?
Abstract
Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.
Copyright © 2013 Elsevier Inc. All rights reserved.
Comment on
-
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.Cancer Cell. 2013 Feb 11;23(2):143-58. doi: 10.1016/j.ccr.2012.12.008. Epub 2013 Jan 24. Cancer Cell. 2013. PMID: 23352126 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
